Comparison of 7‐day and 14‐day Proton Pump Inhibitor‐Containing Triple Therapy for Helicobacter pylori Eradication: Neither Treatment Duration Provides Acceptable Eradication Rate in Korea
- 15 January 2007
- journal article
- clinical trial
- Published by Wiley in Helicobacter
- Vol. 12 (1), 31-35
- https://doi.org/10.1111/j.1523-5378.2007.00468.x
Abstract
Background and Aims: Although triple combination therapy containing a proton pump inhibitor (PPI) and two antibiotics is considered as a standard regimen for the first‐line anti‐Helicobacter pylori treatment, there are still debates on the ideal duration of treatment. The aim of this study was to compare the efficacies of 7‐day and 14‐day PPI‐containing triple therapy. Materials and Methods: This study was performed in a randomized, multicenter, prospective manner. After upper gastrointestinal endoscopy, H. pylori‐infected patients with a gastric ulcer and/or a duodenal ulcer were randomly assigned to a PAC7 group (omeprazole 20 mg or equivalent dose of other PPIs, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days) or to a PAC14 group (the same regimen as the PAC7 group but for 14 days). H. pylori status was evaluated by 13C urea breath test 5 weeks after anti‐ulcer treatment completion. Results: A total of 598 patients were enrolled; 337 were randomized to the PAC7 group and 261 to the PAC14 group. The two groups were comparable in terms of baseline characteristics. The eradication rates of the PAC7 group were not inferior to those of the PAC14 group in both intention‐to‐treat analysis (71.2% vs. 75.5%) and per‐protocol analysis (83.6% vs. 86.6%). Incidences of adverse events were comparable. Conclusions: Although the 7‐day PPI‐containing triple anti‐H. pylori therapy is not inferior to the 14‐day therapy, neither treatment duration provides acceptable eradication rate reaching 90% in per‐protocol analysis. New combination regimen with higher efficacy should be developed as a first‐line eradication therapy for H. pylori in Korea.Keywords
This publication has 16 references indexed in Scilit:
- Distribution of Antibiotic MICs for Helicobacter pylori Strains over a 16-Year Period in Patients from Seoul, South KoreaAntimicrobial Agents and Chemotherapy, 2004
- Seven‐day therapy for Helicobacter pylori in the United StatesAlimentary Pharmacology & Therapeutics, 2004
- Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus ReportAlimentary Pharmacology & Therapeutics, 2002
- A meta‐analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 2000
- The GU‐MACH study: the effect of 1‐week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcerAlimentary Pharmacology & Therapeutics, 1999
- Randomized comparison of differing periods of twice‐a‐day triple therapy for the eradication of Helicobacter pyloriAlimentary Pharmacology & Therapeutics, 1996
- Eradication of Helicobacter pylori Using One‐week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I StudyHelicobacter, 1996
- Prospective evaluation of the macrolide antibiotic dirithromycin for the treatment of Helicobacter pylori.Alimentary Pharmacology & Therapeutics, 1996
- Comparison of One or Two Weeks of Lansoprazole, Amoxicillin, and Clarithromycin in the Treatment of Helicobacter pyloriHelicobacter, 1996
- Effect of Treatment of Helicobacter pylori Infection on the Long-term Recurrence of Gastric or Duodenal UlcerAnnals of Internal Medicine, 1992